Healthcare - Biotechnology - NASDAQ - US
$ 0.4906
-5.83 %
$ 20.3 M
Market Cap
-0.52
P/E
CASH FLOW STATEMENT
-33.3 M
OPERATING CASH FLOW
55.8 M
INVESTING CASH FLOW
49.1 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Spruce Biosciences, Inc.
| Net Income | -47.9 M |
| Depreciation & Amortization | 70 K |
| Capital Expenditures | -7 K |
| Stock-Based Compensation | 4.62 M |
| Change in Working Capital | 10.4 M |
| Others | 8.05 M |
| Free Cash Flow | -33.3 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | |
|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | ||||||
| Net Income | (47.9) | (46.2) | (42.3) | (29.5) | (13.1) | (9.9) |
| Depreciation & Amortization | 70 K | 74 K | 68 K | 36 K | 12 K | 1 K |
| Deferred Income Tax | 0 | 0 | 0.1 | 0 | (0.4) | 0 |
| Stock Based Compensation | 4.6 | 3.6 | 4.0 | 0.8 | 0.2 | 0.1 |
| Other Operating Activities | (0.4) | (0.3) | 0.3 | 66 K | 0.4 | (1.6) |
| Change in Working Capital | 10.4 | 1.1 | 2.0 | 1.2 | 0.3 | 1.2 |
| Cash From Operations | (33.3) | (41.7) | (35.9) | (27.5) | (12.6) | (8.6) |
| INVESTING CASH FLOW | ||||||
| Capital Expenditures | 7 K | 8 K | 93 K | 74 K | 4 K | 0 |
| Other Items | 55.8 | 23.7 | (79.1) | 0 | 0 | 0 |
| Cash From Investing Activities | 55.8 | 23.7 | (79.2) | 74 K | 4 K | 0 |
| FINANCING CASH FLOW | ||||||
| Common Stock Repurchased | 0 | 40 K | 0.1 | 0 | 0 | 0 |
| Total Debt Repaid | (1.6) | 0 | 0.2 | 0 | 4.5 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (2.9) | (0.2) | 0.4 | 87.7 | 7.9 | 0 |
| Cash From Financing Activities | 49.1 | (0.2) | 0.6 | 181.0 | 12.4 | 0 |
| CHANGE IN CASH | ||||||
| Net Change In Cash | 71.6 | (18.2) | (114.4) | 153.4 | (0.2) | (8.6) |
| FREE CASH FLOW | ||||||
| Free Cash Flow | (33.3) | (41.7) | (36.0) | (27.6) | (12.6) | (8.6) |